SCHEDULE
OF AMOUNTS RECEIVABLE AND PREPAID EXPENSES
| | |
2026 | | |
2025 | |
| | |
July 31, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Directors and officers insurance | |
$ | 669,173 | | |
$ | 564,794 | |
| Prepaid expense (a) | |
| 813,987 | | |
| 1,394,439 | |
| Other prepaids and account receivable | |
| 21,068 | | |
| 101,062 | |
| Amounts receivable and
prepaid expenses | |
$ | 1,504,228 | | |
$ | 2,060,295 | |
| |
(a) |
Prepaid
expenses as of July 31, 2026 include amounts paid to certain vendors in respect of the Company’s ongoing pivotal phase III
trial study. These amounts are amortized on a straight-line basis over the period of the clinical trial. Prepaid expenses estimated
to be expensed within 12 months amount to $813,987 in 2026 compared to $1,394,439 in 2025 and are included in current assets, whilst
the balance, extending longer than 12 months, amounts to $315,703 in 2026 as compared to $717,508 in 2025 and is included in non-current
assets under long-term prepaid expenses. |
|